These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Variation characteristics and clinical significance of Ma Q; Liu Y; Zhao H; Guo Y; Sun W; Hu R Hematology; 2024 Dec; 29(1):2387878. PubMed ID: 39140716 [No Abstract] [Full Text] [Related]
4. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms. Shah MV; Tran ENH; Shah S; Chhetri R; Baranwal A; Ladon D; Shultz C; Al-Kali A; Brown AL; Chen D; Scott HS; Greipp P; Thomas D; Alkhateeb HB; Singhal D; Gangat N; Kumar S; Patnaik MM; Hahn CN; Kok CH; Tefferi A; Hiwase DK Blood Cancer J; 2023 Apr; 13(1):51. PubMed ID: 37041128 [TBL] [Abstract][Full Text] [Related]
5. [Clinical and prognostic values of TP53 mutation in patients with acute myeloid leukemia]. Zhang Y; Hu XX; Gao L; Ni X; Chen J; Chen L; Zhang WP; Yang JM; Wang JM Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):932-938. PubMed ID: 31856443 [No Abstract] [Full Text] [Related]
6. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. Daver NG; Iqbal S; Renard C; Chan RJ; Hasegawa K; Hu H; Tse P; Yan J; Zoratti MJ; Xie F; Ramsingh G J Hematol Oncol; 2023 Mar; 16(1):19. PubMed ID: 36879351 [TBL] [Abstract][Full Text] [Related]
7. Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia. Chen Y; Zheng J; Weng Y; Wu Z; Luo X; Qiu Y; Lin Y; Hu J; Wu Y Ann Hematol; 2024 Apr; 103(4):1211-1220. PubMed ID: 38409598 [TBL] [Abstract][Full Text] [Related]
8. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. Loke J; Labopin M; Craddock C; Cornelissen JJ; Labussière-Wallet H; Wagner-Drouet EM; Van Gorkom G; Schaap NPM; Kröger NM; Veelken JH; Rovira M; Menard AL; Bug G; Bazarbachi A; Giebel S; Brissot E; Nagler A; Esteve J; Mohty M Cancer; 2022 Aug; 128(15):2922-2931. PubMed ID: 35612815 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and characteristics of patients with Bewersdorf JP; Shallis RM; Gowda L; Wei W; Hager K; Isufi I; Kim TK; Pillai MM; Seropian S; Podoltsev NA; Gore SD; Siddon AJ; Zeidan AM Leuk Lymphoma; 2020 Sep; 61(9):2180-2190. PubMed ID: 32362171 [TBL] [Abstract][Full Text] [Related]
10. [Clinical features and survival analysis in non-M(3) acute myeloid leukemia patients with ASXL1 gene mutation]. Jia WB; Liu JT; Yang XY; Wu HY; Wei YH; Can C; Wang RQ; He N; Gu CY; Ma DX; Ji CY Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):833-840. PubMed ID: 36709197 [No Abstract] [Full Text] [Related]
11. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations. DiGennaro J; Sallman DA Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186 [TBL] [Abstract][Full Text] [Related]
12. TP53 in MDS and AML: Biological and clinical advances. Zhao Y; Chen W; Yu J; Pei S; Zhang Q; Shi J; Huang H; Zhao Y Cancer Lett; 2024 Apr; 588():216767. PubMed ID: 38417666 [TBL] [Abstract][Full Text] [Related]
13. Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia. Bahaj W; Kewan T; Gurnari C; Durmaz A; Ponvilawan B; Pandit I; Kubota Y; Ogbue OD; Zawit M; Madanat Y; Bat T; Balasubramanian SK; Awada H; Ahmed R; Mori M; Meggendorfer M; Haferlach T; Visconte V; Maciejewski JP J Hematol Oncol; 2023 Aug; 16(1):91. PubMed ID: 37537667 [TBL] [Abstract][Full Text] [Related]